Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Yi Ba

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-0255-4376; OpenAlex author ID A5037658093, A5101475780, A5122817943. Sources: ClinicalTrials.gov.

Their work

Papers
9 (first author 0, last author 6)
Trials
1
Grants
0
Labs led
1
Collaborators
32
Papers, trials and grants by year

2012: 1 paper, 1 trial · 2013: none · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 9

  1. Treatment of metastatic pancreatic cancer with concurrent BRAF V600E mutation and germline BRCA2 mutation: a case report. Last author DOI 10.21037/cco-2025-aw-132↗
  2. Efficacy and safety of multi-target tyrosine kinase inhibitor AL2846 combined with gemcitabine in pancreatic cancer. Last author DOI 10.1007/s10637-024-01485-5↗
  3. Advances in medical treatment of advanced hepatobiliary and pancreatic cancer in 2022. Last author DOI 10.1002/cai2.60↗
  4. iRGD-modified exosomes encapsulate anti-miR-25-3p for targeted pancreatic cancer therapy Last author DOI 10.21203/rs.3.rs-2470450/v1↗
  5. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Co-author DOI 10.1186/s40880-019-0367-7↗
  6. Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis. Last author DOI 10.1159/000447872↗
  7. S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, m… Co-author DOI 10.1634/theoncologist.2014-0223↗
  8. The pretreatment platelet and plasma fibrinogen level correlate with tumor progression and metastasis in patients with pancreatic cancer. Last author DOI 10.3109/09537104.2013.827782↗
  9. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Co-author DOI 10.1373/clinchem.2011.172767↗

Trials 1

  1. Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer Study chair NCT01598584↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ting Deng · 5 shared papers, 2014–2025 · strength 0.59
  2. Zhi Ji · 2 shared papers, 2023–2025 · strength 0.40
  3. Le Zhang · 2 shared papers, 2019–2023 · strength 0.35
  4. Xiaoting Ma · 1 shared paper, 2026 · strength 0.33
  5. Yuejuan Cheng · 1 shared paper, 2026 · strength 0.33
  6. Rui Liu · 1 shared paper, 2023 · strength 0.26
  7. Rui Liu · 1 shared paper, 2025 · strength 0.22
  8. Rui Liu · 1 shared paper, 2023 · strength 0.18
  9. Duo Zuo · 1 shared paper, 2023 · strength 0.18
  10. Ning Wang · 1 shared paper, 2023 · strength 0.18
  11. Tiansuo Zhao · 1 shared paper, 2023 · strength 0.18
  12. Cheng Wang · 2 shared papers, 2012–2016 · strength 0.09
  13. Rui Liu · 2 shared papers, 2012–2016 · strength 0.09
  14. Yaozong Yuan · 2 shared papers, 2012–2016 · strength 0.09
  15. Weiyan Yao · 2 shared papers, 2012–2016 · strength 0.09
  16. Zhi‐Qiang Wang · 1 shared paper, 2019 · strength 0.09
  17. Fei Zhang · 1 shared paper, 2019 · strength 0.09
  18. De‐Shen Wang · 1 shared paper, 2019 · strength 0.09
  19. Feng‐Hua Wang · 1 shared paper, 2019 · strength 0.09
  20. Rui‐Hua Xu · 1 shared paper, 2019 · strength 0.09
  21. Wei Wang · 1 shared paper, 2019 · strength 0.09
  22. Yuhong Li · 1 shared paper, 2019 · strength 0.09
  23. Fei-Jiao Ge · 1 shared paper, 2014 · strength 0.04
  24. Haiyan Wang · 1 shared paper, 2014 · strength 0.04
  25. Rui Liu · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.